drugset
drugset / Trial / NCT04257500

Does Vaginal Delivery of Combined Hormonal Contraception Affect the Risk of Metabolic Syndrome in Overweight/Obese Women With PCOS

NCT04257500 ↗

Phase 4 Completed 22 enrolled Andrea Roe, MD, MPH
NaSingle-groupOpen-labelPrevention

Summary

A prospective study to determine the metabolic effects of the contraceptive vaginal ring among overweight and obese women with polycystic ovary syndrome (PCOS). We will recruit a total of 40 participants and study use of the vaginal ring over a 4-month period.

Timeline

Start
2020-09-03
Primary completion
2025-08-22
Completion
2025-08-22

Drugs

EvaluationDrugModalityDoseRoute
Subject Etonogestrel/ethinyl estradiol Unknown 15 ug Other
Subject Etonogestrel/ethinyl estradiol Unknown 120 ug Other

Indications

polycystic ovary syndrome